Publication Name	World Journal of Gastroenterology
Manuscript ID	5553
Country	Belgium

Received	2013-09-14 11:30
Peer-Review Started	2013-09-15 16:17
To Make the First Decision	2013-10-22 16:09
Return for Revision	2013-10-23 19:10
Revised	2013-11-12 20:29
Second Decision	2013-11-29 10:51
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2013-11-29 23:50
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-12-27 11:06
Publish the Manuscript Online	2014-01-20 17:10

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Editorial
Article Title	Advances in radiotherapy and targeted therapies for rectal cancer
Manuscript Source	Invited Manuscript
All Author List	Alexandra Sermeus, Wim Leonard, Benedikt Engels and Mark De Ridder
Funding Agency and Grant Number	Funding Agency Grant Number Vlaamse Liga tegen Kanker
Corresponding Author	Mark De Ridder, MD, PhD, Professor, UZ Brussel, Vrije Universiteit Brussel, Departments of Radiotherapy, Laarbeeklaan 101, B-1090 Brussels, Belgium. mark.deridder@uzbrussel.be
Key Words	Rectal cancer; Image-guided radiotherapy; Intensity-modulated radiotherapy; Biomarkers; Targeted therapies; Myeloid-derived suppressor cells
Core Tip	The stepwise implementation of intensity-modulated and image-guided radiation therapy enabled us to anatomically sculpt dose delivery and prescribe a simultaneous integrated boost, thus reducing treatment related toxicity. However, distant control remains unsatisfactory and indicates an urgent need for biomarkers of tumor spread. The immune landscape of colorectal cancer is now better clarified with regard to protumor N2 neutrophils and myeloid-derived suppressor cells (MDSC) that emerge as useful prognostic biomarkers. The growing list of anti-MDSC agents shows promising ability to boost antitumor T-cell immunity. Therefore, integration of genetic and immune biomarkers is the next logical step towards effective targeted therapies in the context of personalized cancer treatment.
Publish Date	2014-01-20 17:10
Citation	Sermeus A, Leonard W, Engels B, De Ridder M. Advances in radiotherapy and targeted therapies for rectal cancer. World J Gastroenterol 2014; 20(1): 1-5
URL	http://www.wjgnet.com/1007-9327/full/v20/i1/1.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i1.1

Manuscript File	5553-Review.docx
Answering Reviewers	5553-Answering reviewers.pdf
Copyright License Agreement	5553-Copyright assignment.pdf
Peer-review Report	5553-Peer review(s).pdf
Scientific Editor Work List	5553-Scientific editor work list.doc